NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...

Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...